BioCentury | Oct 30, 2006
Company News

Adventrx, Theragenex deal

...first product based on ANX-211 in 2007. ANX gained the compound through its acquisition of SD Pharmaceuticals Inc....
BioCentury | May 8, 2006
Company News

Adventrx, SD Pharma deal

...its price was $4.89 (see BioCentury, April 17). Adventrx Pharmaceuticals Inc. (ANX), San Diego, Calif. SD Pharmaceuticals Inc....
BioCentury | Apr 17, 2006
Company News

Adventrx, SD Pharma deal

...development for cancer (see BioCentury, Oct. 10, 2005). Adventrx Pharmaceuticals Inc. (ANX), San Diego, Calif. SD Pharmaceuticals Inc....
BioCentury | Apr 10, 2006
Clinical News

Vinorelbine emulsion: Pivotal trial start

...file an IND in the third quarter, and hopes to submit an NDA in 2007. SD Pharmaceuticals Inc....
BioCentury | Apr 10, 2006
Clinical News

SD Pharma preclinical data

...of Cancer Research in Washington. Navelbine is marketed by GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.). SD Pharmaceuticals Inc....
BioCentury | Jan 16, 2006
Clinical News

SD Pharma preclinical data

...does not contain polysorbate 80. Taxotere is marketed by sanofi-aventis Group (Euronext:SAN; SNY, Paris, France). SD Pharmaceuticals Inc....
BioCentury | Jan 2, 2006
Clinical News

SD Pharma preclinical data

...does not contain polysorbate 80. Taxotere is marketed by sanofi-aventis Group (Euronext:SAN; SNY, Paris, France). SD Pharmaceuticals Inc....
BioCentury | Jan 2, 2006
Clinical News

SD Pharma preclinical data

...does not contain polysorbate 80. Taxotere is marketed by sanofi-aventis Group (Euronext:SAN; SNY, Paris, France). SD Pharmaceuticals Inc....
BioCentury | Oct 10, 2005
Company News

Adventrx, SD Pharma deal

...have a pre-IND meeting with FDA in December. Adventrx Pharmaceuticals Inc. (ANX), San Diego, Calif. SD Pharmaceuticals Inc....
Items per page:
1 - 9 of 9
BioCentury | Oct 30, 2006
Company News

Adventrx, Theragenex deal

...first product based on ANX-211 in 2007. ANX gained the compound through its acquisition of SD Pharmaceuticals Inc....
BioCentury | May 8, 2006
Company News

Adventrx, SD Pharma deal

...its price was $4.89 (see BioCentury, April 17). Adventrx Pharmaceuticals Inc. (ANX), San Diego, Calif. SD Pharmaceuticals Inc....
BioCentury | Apr 17, 2006
Company News

Adventrx, SD Pharma deal

...development for cancer (see BioCentury, Oct. 10, 2005). Adventrx Pharmaceuticals Inc. (ANX), San Diego, Calif. SD Pharmaceuticals Inc....
BioCentury | Apr 10, 2006
Clinical News

Vinorelbine emulsion: Pivotal trial start

...file an IND in the third quarter, and hopes to submit an NDA in 2007. SD Pharmaceuticals Inc....
BioCentury | Apr 10, 2006
Clinical News

SD Pharma preclinical data

...of Cancer Research in Washington. Navelbine is marketed by GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.). SD Pharmaceuticals Inc....
BioCentury | Jan 16, 2006
Clinical News

SD Pharma preclinical data

...does not contain polysorbate 80. Taxotere is marketed by sanofi-aventis Group (Euronext:SAN; SNY, Paris, France). SD Pharmaceuticals Inc....
BioCentury | Jan 2, 2006
Clinical News

SD Pharma preclinical data

...does not contain polysorbate 80. Taxotere is marketed by sanofi-aventis Group (Euronext:SAN; SNY, Paris, France). SD Pharmaceuticals Inc....
BioCentury | Jan 2, 2006
Clinical News

SD Pharma preclinical data

...does not contain polysorbate 80. Taxotere is marketed by sanofi-aventis Group (Euronext:SAN; SNY, Paris, France). SD Pharmaceuticals Inc....
BioCentury | Oct 10, 2005
Company News

Adventrx, SD Pharma deal

...have a pre-IND meeting with FDA in December. Adventrx Pharmaceuticals Inc. (ANX), San Diego, Calif. SD Pharmaceuticals Inc....
Items per page:
1 - 9 of 9